{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:22Z","timestamp":1789596382297,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,9,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Chemoimmunotherapy has been the standard approach for untreated indolent B-cell lymphoma. We hypothesized that initial use of the CD3\/CD20 bispecific mosunetuzumab followed by response-adapted polatuzumab vedotin and obinutuzumab would yield an optimized chemotherapy-free approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Previously untreated patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL) with indication for treatment received eight cycles of mosunetuzumab. Those not achieving a complete response (CR) by positron emission tomography-computed tomography (PET-CT) following mosunetuzumab could go on to receive six cycles of polatuzumab vedotin and obinutuzumab. The primary end point was best overall response rate (ORR) of CR by fluorodeoxyglucose-PET-CT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The 42 enrolled patients had a median age of 60 years (range, 36-83), 39 were stage III to IV (93%), 37 (88%) had FL, and 13 (31%) had bulk &gt;7 cm. The end-of-treatment ORR and CR rates were 100% and 86%, respectively. The ORR and CR to mosunetuzumab alone were 100% and 71%, respectively. With a median follow-up of 34 months, the 2-year progression-free survival (PFS) was 89% (95% CI, 80 to 100) and the 2-year overall survival was 100%. The four progression events included CD20 loss (2) and histologic transformation (2). Cytokine release syndrome occurred in 27 patients (64%), but all were grade 1. No patients required tocilizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Single-agent mosunetuzumab as well as response-adapted polatuzumab vedotin and obinutuzumab yield encouraging CR rates and PFS with limited toxicity among previously untreated patients with FL and MZL. This chemotherapy-free strategy may provide a template for larger study designs for personalized approaches in this population that balances efficacy with safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02906","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:59:16Z","timestamp":1786737556000},"page":"2625-2633","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct05169658","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-712X","authenticated-orcid":false,"given":"Christina","family":"Poh","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-8288","authenticated-orcid":false,"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra S.","family":"Ujjani","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Raghunathan","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maloney","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Gausman","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-2247","authenticated-orcid":false,"given":"David A.","family":"Russler-Germain","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-4651","authenticated-orcid":false,"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, CA"},{"name":"Foresight Diagnostics, Boulder, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"},{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-197897"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3324\/haematol.2024.285245","article-title":"Bispecific antibodies in follicular lymphoma","volume":"110","author":"Nizamuddin IA","year":"2025","unstructured":"Nizamuddin IA, Bartlett NL: Bispecific antibodies in follicular lymphoma. Haematologica 110:1472-1482, 2025","journal-title":"Haematologica"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30618-1"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189824"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26400"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01712"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28719"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02327"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205046"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193022"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-021-01627-8"},{"key":"e_1_3_10_23_2","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch RC","year":"2023","unstructured":"Lynch RC, Ujjani CS, Poh C, et al: Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood 141:2576-2586, 2023","journal-title":"Blood"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.0042"},{"key":"e_1_3_10_25_2","article-title":"SWOG 2308: Randomized phase III study of mosunetuzumab versus rituximab for low-tumor burden follicular lymphoma","author":"Ghosh N","unstructured":"Ghosh N, Bellasea S, Li H, et al: SWOG 2308: Randomized phase III study of mosunetuzumab versus rituximab for low-tumor burden follicular lymphoma. JCO Oncol Adv 10.1200\/OA-25-00037","journal-title":"JCO Oncol Adv"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:00:28Z","timestamp":1789596028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":24,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026,9,20]]}},"alternative-id":["10.1200\/JCO-25-02906"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02906","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"2025-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}